# PepGen Inc. (PEPG)

Source: https://www.quantisnow.com/company/PEPG
Generated: 2026-11-05T08:32:28.163Z

- Ticker: PEPG
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2022
- SEC CIK: 0001835597
- Website: https://www.pepgen.com

## About

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.

## Latest PEPG news and filings

- 2026-08-06 11:40 UTC [SEC Form 8-K] [PepGen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/pepgen-inc-filed-sec-form-8-k-results-of-operations-and-6667344)
- 2026-08-06 11:32 UTC [PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights](https://www.quantisnow.com/insight/pepgen-reports-second-quarter-2026-financial-results-and-recent-corporate-6667313)
- 2026-08-06 11:30 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by PepGen Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-pepgen-inc-6667303)
- 2026-08-06 11:30 UTC [PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review](https://www.quantisnow.com/insight/pepgen-to-advance-pgn-edodm1-into-highest-dose-cohort-in-phase-6667281)
- 2026-07-06 20:05 UTC [Leadership Update] [Kalaris Appoints Laurie Keating to Board of Directors](https://www.quantisnow.com/insight/kalaris-appoints-laurie-keating-to-board-of-directors-6628013)
- 2026-06-22 20:31 UTC [SEC Form 4] [SEC Form 4 filed by Director Ra Capital Management, L.P.](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-ra-capital-management-lp-6610932)
- 2026-06-22 20:30 UTC [SEC Form 8-K] [PepGen Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders](https://www.quantisnow.com/insight/pepgen-inc-filed-sec-form-8-k-submission-of-matters-to-6610907)
- 2026-06-22 20:13 UTC [SEC Form 4] [SEC Form 4 filed by Director Wyman Lisa](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-wyman-lisa-6610761)
- 2026-06-22 20:12 UTC [SEC Form 4] [SEC Form 4 filed by Director Resnick Joshua](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-resnick-joshua-6610743)
- 2026-06-22 20:10 UTC [SEC Form 4] [SEC Form 4 filed by Director Mayer Howard](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-mayer-howard-6610728)
- 2026-06-22 20:08 UTC [SEC Form 4] [SEC Form 4 filed by Director Finer Mitchell H.](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-finer-mitchell-h-6610699)
- 2026-06-22 20:06 UTC [SEC Form 4] [SEC Form 4 filed by Director Dable Habib J](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-dable-habib-j-6610680)
- 2026-06-22 20:05 UTC [SEC Form 4] [SEC Form 4 filed by Director Henson Heidi](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-henson-heidi-6610649)
- 2026-06-22 20:03 UTC [SEC Form 4] [SEC Form 4 filed by Director Keating Laurie](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-keating-laurie-6610631)
- 2026-06-16 12:08 UTC [Analyst Coverage Initiated] [Craig Hallum initiated coverage on PepGen with a new price target](https://www.quantisnow.com/insight/craig-hallum-initiated-coverage-on-pepgen-with-a-new-price-6603981)
- 2026-05-26 20:43 UTC [SEC Form 4] [Chief Technical Officer Kasraian Kasra sold $1,739 worth of shares (1,233 units at $1.41) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 50,074 units (SEC Form 4) (withholding tax)](https://www.quantisnow.com/insight/chief-technical-officer-kasraian-kasra-sold-1739-worth-of-shares-6572721)
- 2026-05-22 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by PepGen Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-pepgen-inc-6568717)
- 2026-05-21 11:30 UTC [SEC Form 8-K] [PepGen Inc. filed SEC Form 8-K: Regulation FD Disclosure](https://www.quantisnow.com/insight/pepgen-inc-filed-sec-form-8-k-regulation-fd-disclosure-6566358)
- 2026-05-21 11:00 UTC [PepGen Announces Presentations at the 15th International Myotonic Dystrophy Consortium Highlighting Clinical Data from the PGN-EDODM1 Program](https://www.quantisnow.com/insight/pepgen-announces-presentations-at-the-15th-international-myotonic-dystrophy-consortium-6566273)
- 2026-05-19 16:03 UTC [SEC Form S-3] [SEC Form S-3 filed by PepGen Inc.](https://www.quantisnow.com/insight/sec-form-s-3-filed-by-pepgen-inc-6562192)
- 2026-05-15 21:48 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by PepGen Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-pepgen-inc-6558569)
- 2026-05-15 20:19 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by PepGen Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-pepgen-inc-6557642)
- 2026-05-12 20:10 UTC [SEC Form 8-K] [PepGen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/pepgen-inc-filed-sec-form-8-k-results-of-operations-and-6548048)
- 2026-05-12 20:05 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by PepGen Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-pepgen-inc-6547966)
- 2026-05-12 20:05 UTC [PepGen Reports First Quarter 2026 Financial Results and Recent Corporate Highlights](https://www.quantisnow.com/insight/pepgen-reports-first-quarter-2026-financial-results-and-recent-corporate-6547838)
- 2026-04-28 20:07 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by PepGen Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-pepgen-inc-6518589)
- 2026-04-28 20:05 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by PepGen Inc.](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-pepgen-inc-6518524)
- 2026-03-30 21:30 UTC [SEC Form 8-K] [PepGen Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/pepgen-inc-filed-sec-form-8-k-regulation-fd-disclosure-other-6476731)
- 2026-03-30 20:05 UTC [Earnings Date] [PepGen Announces Topline Results from Lowest Dose (5 mg/kg) MAD Cohort in the Ongoing Phase 2 FREEDOM2 Study Demonstrating Favorable Safety, Splicing and vHOT Data](https://www.quantisnow.com/insight/pepgen-announces-topline-results-from-lowest-dose-5-mgkg-mad-6476519)
- 2026-03-11 20:06 UTC [SEC Form SCHEDULE 13G filed by PepGen Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-pepgen-inc-6441997)
- 2026-03-06 21:14 UTC [SEC Form 4] [EVP, Head of R&D Streck Paul sold $11,709 worth of shares (1,879 units at $6.23), decreasing direct ownership by 2% to 76,226 units (SEC Form 4)](https://www.quantisnow.com/insight/evp-head-of-rd-streck-paul-sold-11709-worth-of-6434929)
- 2026-03-06 21:12 UTC [SEC Form 4] [Chief Financial Officer Donnelly Noel sold $12,988 worth of shares (2,084 units at $6.23), decreasing direct ownership by 2% to 111,603 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-financial-officer-donnelly-noel-sold-12988-worth-of-shares-6434909)
- 2026-03-06 21:09 UTC [SEC Form 4] [President and CEO Mcarthur James G sold $32,876 worth of shares (5,275 units at $6.23), decreasing direct ownership by 2% to 296,326 units (SEC Form 4)](https://www.quantisnow.com/insight/president-and-ceo-mcarthur-james-g-sold-32876-worth-of-6434870)
- 2026-03-04 22:02 UTC [SEC Form 8-K] [PepGen Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/pepgen-inc-filed-sec-form-8-k-regulation-fd-disclosure-financial-6430178)
- 2026-03-04 21:20 UTC [SEC Form S-8] [SEC Form S-8 filed by PepGen Inc.](https://www.quantisnow.com/insight/sec-form-s-8-filed-by-pepgen-inc-6429623)
- 2026-03-04 21:15 UTC [SEC Form 10-K] [SEC Form 10-K filed by PepGen Inc.](https://www.quantisnow.com/insight/sec-form-10-k-filed-by-pepgen-inc-6429526)
- 2026-03-04 21:11 UTC [SEC Form 8-K] [PepGen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/pepgen-inc-filed-sec-form-8-k-results-of-operations-and-6429385)
- 2026-03-04 21:03 UTC [PepGen Announces Regulatory Updates on FREEDOM2](https://www.quantisnow.com/insight/pepgen-announces-regulatory-updates-on-freedom2-6429165)
- 2026-03-03 12:00 UTC [Conference Announcement] [PepGen to Participate in the Leerink Global Healthcare Conference](https://www.quantisnow.com/insight/pepgen-to-participate-in-the-leerink-global-healthcare-conference-6423709)
- 2026-03-02 22:09 UTC [SEC Form 4] [Chief Business & Legal Officer Vittiglio Joseph was granted 30,717 shares, increasing direct ownership by 88% to 65,717 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-business-legal-officer-vittiglio-joseph-was-granted-30717-shares-6422727)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/PEPG
- Earnings history: https://www.quantisnow.com/earnings/PEPG
- Dividend history: https://www.quantisnow.com/dividends/PEPG
- Insider transactions: https://www.quantisnow.com/insiders/PEPG
- Options chain: https://www.quantisnow.com/options/PEPG
- SEC 8-K filings only: https://www.quantisnow.com/company/PEPG/8-k
- RSS and alerts for PEPG: https://www.quantisnow.com/docs/rss-feeds.md